InsuranceDekho to get $20 mn funding from GirnarSoft for branding, others

Christel Deskins

InsuranceDekho on Tuesday said GirnarSoft has committed USD 20 million (around Rs 147 crore) investment in the company. InsuranceDekho, an omni channel insurance platform, is a subsidiary of GirnarSoft. The funds will be invested in branding, and strengthening the technology, product […]


InsuranceDekho on Tuesday said GirnarSoft has committed USD 20 million (around Rs 147 crore) investment in the company.


InsuranceDekho, an omni channel insurance platform, is a subsidiary of GirnarSoft.



The funds will be invested in branding, and strengthening the technology, product and sales teams, InsuranceDekho said in a statement.


The funds will also be used to strengthen InsuranceDekho’s transaction businesses and expand its footprint deeper into the country.


InsuranceDekho recently announced plans to onboard 1 lakh insurance advisors across the country. It has already enrolled 20,000 advisors successfully, the company said.


“This proposed fund infusion is our vote of confidence in their ability to build India’s most enduring insuretech business in India,” said Amit Jain, CEO and co-founder of GirnarSoft.


The other ventures of GirnarSoft are CarDekho.com, Zigwheels.com and gaadi.com.


“This new capital infusion will be used to expand our digital footprint. We are already a force to reckon with in the B2B space. With this round we aim to invest in branding and marketing to further strengthen our B2C platform which has been seeing strong traction over the last 2 quarters,” InsuranceDekho CEO and co-founder Ankit Agrawal said.


InsuranceDekho enables customers to compare different insurance policies, both online and offline, and has tie-ups with over 26 general insurance companies.


The company is currently at an annualized run rate of 20 lakh policies and intends to close March 2021 at an annualized run rate of 36 lakh policies, it said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Next Post

FDA proposes a 'modest' change to a rule for policing off-label marketing

After years of controversy, the Food and Drug Administration has issued a proposed rule to clarify when manufacturers would have to update product labeling to reflect unapproved uses of their medicines. In doing so, the agency has left intact a decades-old rule that stated drug makers must update labeling if […]